Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The incidence and prevalence of food allergy (FA) is increasing. While several studies have established the safety and efficacy of early introduction of single allergens in infants for the prevention of FA, the exact dose, frequency, and number of allergens that can be safely introduced to infants, particularly in those at high or low risk of atopy, are still unclear. This 1-year pilot study evaluated the safety of the early introduction of single foods (milk, egg, or peanut) vs. two foods (milk/egg, egg/peanut, milk/peanut) vs. multiple foods (milk/egg/peanut/cashew/almond/shrimp/walnut/wheat/salmon/hazelnut at low, medium, or high doses) vs. no early introduction in 180 infants between 4-6 months of age. At the end of the study, they were evaluated for plasma biomarkers associated with food reactivity via standardized blood tests. Two to four years after the start of the study, participants were evaluated by standardized food challenges. The serving sizes for the single, double, and low dose mixtures were 300 mg total protein per day. The serving sizes for the medium and high dose mixtures were 900 mg and 3000 mg total protein, respectively. Equal parts of each protein were used for double or mixture foods. All infants were breastfed until at least six months of age. The results demonstrate that infants at either high or low risk for atopy were able to tolerate the early introduction of multiple allergenic foods with no increases in any safety issues, including eczema, FA, or food protein induced enterocolitis. The mixtures of foods at either low, medium, or high doses demonstrated trends for improvement in food challenge reactivity and plasma biomarkers compared to single and double food introductions. The results of this study suggest that the early introduction of foods, particularly simultaneous mixtures of many allergenic foods, may be safe and efficacious for preventing FA and can occur safely. These results need to be confirmed by larger randomized controlled studies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879339PMC
http://dx.doi.org/10.3390/nu14040737DOI Listing

Publication Analysis

Top Keywords

early introduction
24
medium high
12
food allergy
8
pilot study
8
introduction single
8
infants high
8
high low
8
low risk
8
risk atopy
8
study evaluated
8

Similar Publications

Clinical, virological, and antibody profiles of overlapping dengue and chikungunya virus infections in children from southern Colombia.

PLoS Negl Trop Dis

September 2025

División de Inmunología, Programa de Medicina, Facultad de Ciencias de la Salud, Universidad Surcolombiana, Neiva, Huila, Colombia.

Background: Dengue and chikungunya are arboviral diseases with overlapping clinical characteristics. Dengue virus (DENV) is endemic in Colombia, and in 2014/2015, the chikungunya virus (CHIKV) caused an epidemic that resulted in over 350,000 cases. Since then, both viruses have been actively co-circulating.

View Article and Find Full Text PDF

Introduction: Candida auris is a yeast that has a high mortality rate in critically ill patients and is resistant to many antifungal agents enhancing its clinical importance. Our study identifies the risk factors for C. auris invasive infection, antifungal susceptibility, and outcomes.

View Article and Find Full Text PDF

Introduction: This study aimed to examine the impact of Epstein-Barr virus (EBV) infection on the occurrence and prognosis of Henoch-Schönlein purpura (HSP).

Methodology: A total of 120 children diagnosed with HSP were selected as the experimental group, and 100 healthy children who underwent physical examinations were the control group. We compared renal function markers and quantified 24-hour urine protein in HSP children with different EBV infection statuses, and analyzed the association between EBV infection and Henoch-Schönlein purpura nephritis (HSPN).

View Article and Find Full Text PDF

Introduction: Both aging and malignancy are associated with an increased risk of infections, including bloodstream infections. Despite their clinical significance, research concentrating on the epidemiology, outcomes, and risk factors influencing mortality in older cancer patients is still limited. This study aims to examine the epidemiology of bloodstream infections and factors contributing to mortality among older cancer patients.

View Article and Find Full Text PDF

Cytomegalovirus and Epstein-Barr Virus reactivation in steroid-refractory immune checkpoint inhibitor colitis.

J Infect Dev Ctries

August 2025

Gastroenterology Division, Internal Medicine Department, Sultan Qaboos Comprehensive Cancer and Research Center (SQCCCRC), University Medical City (UMC), Muscat, Sultanate of Oman.

Introduction: Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) reactivation are known complications in immunocompromised hosts, particularly transplant recipients. However, their occurrence and clinical implications in patients with solid tumors remain underexplored. The introduction of immune checkpoint inhibitors (ICIs) has transformed cancer therapy, but immune-related adverse events (irAEs), including colitis, are increasingly recognized.

View Article and Find Full Text PDF